On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S. This once-daily, steroid-free cream could become a new standard of care for AD.
CMS Allows State to Offer Medicaid Incentive for Hospitals to Erase Patient Debt
The Centers for Medicare & Medicaid Services (CMS) signed off on a proposal by North Carolina Gov. Roy Cooper’s administration to offer scores of hospitals
July 31, 2024